Top 5 AI-Powered Biotech Stocks to Buy Right Now

4. IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Number of Hedge Fund Holders: 40

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the best biotech stocks to invest in.

TheFly reported on April 14 that Wedbush Securities increased its price target on IDYA from $52 to $58 while maintaining an Outperform rating. The update followed the company’s release of top-line results from its Phase 2/3 OptimUM-02 clinical trial. Management reported that safety outcomes remain consistent with earlier studies, with adverse events generally manageable. The firm also noted that additional detailed findings from the study are expected to be shared at a major medical conference in 2026, which could provide further clarity on the program’s clinical profile and future development potential.

Adding to the company’s operational momentum, on April 6, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) reported that it has begun patient enrollment in a Phase 1 dose-escalation study of IDE574, a first-in-class oral small-molecule therapy designed to inhibit KAT6 and KAT7, two epigenetic targets involved in cancer cell survival.

The early-stage trial will assess safety, pharmacokinetics, and preliminary anti-tumor activity as a monotherapy in patients with advanced solid tumors, including breast, prostate, colorectal, and lung cancers. The program is intended to evaluate a novel dual-mechanism approach aimed at overcoming resistance pathways in oncology and expanding treatment options in multiple high-need cancer indications through epigenetic modulation strategies.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is an AI-driven precision oncology company focused on synthetic lethality-based cancer therapies. It uses machine learning and physics-based drug discovery to develop first-in-class targeted cancer treatments guided by molecular diagnostics.